Vanguard Group Inc Neurocrine Biosciences Inc Transaction History
Vanguard Group Inc
- $5.57 Trillion
- Q4 2024
A detailed history of Vanguard Group Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Vanguard Group Inc holds 10,119,641 shares of NBIX stock, worth $1.1 Billion. This represents 0.02% of its overall portfolio holdings.
Number of Shares
10,119,641
Previous 9,996,960
1.23%
Holding current value
$1.1 Billion
Previous $1.15 Billion
20.02%
% of portfolio
0.02%
Previous 0.02%
Shares
15 transactions
Others Institutions Holding NBIX
# of Institutions
655Shares Held
96.6MCall Options Held
282KPut Options Held
281K-
Black Rock Inc. New York, NY14.2MShares$1.55 Billion0.04% of portfolio
-
State Street Corp Boston, MA4.89MShares$533 Million0.03% of portfolio
-
Dodge & Cox San Francisco, CA3.02MShares$329 Million0.26% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.54MShares$277 Million0.06% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.49MShares$271 Million0.54% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $10.4B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...